In the Englander Institute for Precision Medicine (EIPM), our multi-tiered strategy to personalized medicine employs large-scale genomic sequencing, paired with functional biology to develop the diagnosis and treatment of genetic conditions.
We obtain samples of both normal and tumor tissue to analyze them using genomic sequencing. These data are analyzed to generate the patients’ reports by our distinguished pathologists and are subsequently reviewed by renowned experts in medical oncology, computational biology, and genetics. Our clinical database uses these data for our disease-targeted research that aims to serve even more patients with cancer and other diseases by new drug development for better patient care. We are always looking forward to expanding our research to more diseases to serve even more patients with innovative research to precision medicine, this includes breast cancer, pediatrics, cardiovascular diseases and more.
In EIPM, we aim to deliver more effective treatments by identifying and characterizing genomic changes underlying genetic-based ailments. We collaborate with clinical departments of WCM and NYP to provide a comprehensive interpretation of patient genomes and act as a permanent resource for our clinicians to make effective use of genomic data to optimize patient care. To this effort, we are channeling our efforts towards developing therapies where genomic data contribute significantly to the clinical result and offer hope for transforming health care.
These innovative research areas include:
- Prostate, Bladder and Kidney cancer
- Hematologic Malignancies
- Gastrointestinal Oncology
- Neuro-Oncology
- Endocrine Cancers
Reaching for the stars